Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

25.04 -0.66 (-2.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 26, 2024

Via Benzinga

Why Is Check-Cap (CHEK) Stock Up 44% Today? ↗

March 26, 2024

Check-Cap stock is up on Tuesday with heavy trading as CHEK investors react to news of a business combination with Nobul AI.

Via InvestorPlace

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 26, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket ↗

March 26, 2024

Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001

Via Benzinga

The Latest Analyst Ratings for Stoke Therapeutics ↗

July 31, 2023

Via Benzinga

Why Is Stoke Therapeutics (STOK) Stock Up 99% Today? ↗

March 26, 2024

Stoke Therapeutics stock is up on Tuesday as STOK shares see heavy trading alongside recent positive clinical trial data.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 26, 2024

It's time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning!

Via InvestorPlace

STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023 ↗

March 25, 2024

STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 25, 2024

Via Benzinga

Stoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's Why ↗

March 25, 2024

Stoke Therapeutics reported its fourth-quarter financial results and announced Phase 1/2a end of study data after the bell Monday. The company reported quarterly losses of 60 cents per share which beat...

Via Benzinga

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 25, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

March 25, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory ↗

February 25, 2024

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

Via InvestorPlace

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 17, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

January 08, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 04, 2024

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

December 01, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

November 21, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

November 07, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 17, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 26, 2023

On Tuesday, 386 stocks made new 52-week lows.

Via Benzinga

Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 21, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

September 20, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

September 05, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street ↗

August 16, 2023

This small-cap biotech might be a hidden gem.

Via The Motley Fool

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

August 07, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 02, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

July 27, 2023

During Thursday, 56 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 26, 2023

Wednesday saw 59 companies set new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.